The global poultry medicine market size was estimated at USD 6.72 billion in 2024 and is projected to reach USD 11.90 billion by 2033, growing at a CAGR of 6.70% from 2025 to 2033. The market is advancing due to the rising prevalence of poultry diseases, growing demand for poultry products, and the expansion of commercial poultry farming.

Frequent outbreaks of diseases such as avian influenza, Newcastle disease, and infectious bronchitis have considerably heightened the need for effective pharmaceutical interventions. According to the Food and Agriculture Organization of the United States, as of April 2025, a total of 297 incidents of Highly Pathogenic Avian Influenza (HPAI) in poultry were reported across five geographic regions.

These disease outbreaks result in elevated poultry mortality and reduced productivity, prompting a strong demand for vaccines, antimicrobials, and antiparasitic treatments to mitigate losses. Investments by governments and producers in biosecurity measures and health management practices have increased demand for poultry medicines. With intensive poultry farming practices and dense bird populations becoming more common, the potential for disease transmission rises, reinforcing the necessity for regular medicinal interventions. Surveillance efforts by the World Organization for Animal Health (WOAH) between 2020 and 2023 further highlight the persistent threat of avian diseases globally.

The economic implications of poultry diseases—ranging from reduced productivity to trade limitations—are significant. Consequently, poultry producers increasingly depend on pharmaceuticals such as vaccines, antibiotics, and antiparasitic agents to minimize outbreaks. Moreover, growing biosecurity standards and disease control protocols have driven broader adoption of veterinary pharmaceuticals to maintain animal health, safeguard the food supply chain, and meet compliance requirements in international markets.

The rise in global poultry meat and egg consumption is also a key growth factor. With shifting consumer preferences toward leaner protein sources, poultry remains a top choice due to its affordability, taste, and perceived health benefits. This increasing demand for poultry protein fuels the expansion of industrial poultry farming, thereby amplifying the need for medicines to ensure health, productivity, and disease prevention. Urbanization and economic development in emerging regions further support investments in veterinary products tailored to poultry health.

Order a free sample PDF of the Poultry Medicine Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• North America led the global market with the highest revenue share of 37.42% in 2024.

• In the U.S., the poultry medicine market is influenced by avian flu outbreaks and evolving regulations on antibiotic use.

• Chicken was the dominant species segment with a revenue share of 72.50% in 2024.

• Pharmaceuticals accounted for the largest product segment with a 67.55% revenue share.

• Newcastle disease was the most prevalent disease type, contributing 22.49% to the market in 2024.

Market Size & Forecast

• 2024 Market Size: USD 6.72 Billion

• 2033 Projected Size: USD 11.90 Billion

• CAGR (2025–2033): 6.70%

• Largest Market: North America

• Fastest Growing Region: Asia Pacific

Key Poultry Medicine Company Insights

Leading industry players—including Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, and Virbac—maintain strong positions due to broad product offerings, global market reach, and compliance with regulatory standards. These companies are expanding their footprint through innovations in recombinant and vector-based vaccines, mergers and acquisitions, and entry into emerging markets. While challenges such as stringent regulations, high R&D costs, and reduced antibiotic usage influence the landscape, regional and emerging firms are gaining ground with affordable and targeted product lines suited to local needs.

Key Poultry Medicine Companies

• Boehringer Ingelheim International GmbH
• Zoetis Services LLC
• Vaxxinova International BV
• Merck & Co., Inc.
• Calier
• Elanco
• Hester Biosciences Limited
• Ceva Santé Animale
• Phibro Animal Health Corporation
• Virbac
• Venkys India
• Hipra
• Vetanco
• Kemin Industries, Inc.
• Indovax
• Avimex

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The poultry medicine market is poised for robust growth over the coming years, driven by increased disease prevalence, evolving poultry farming practices, and rising global protein demand. As poultry production becomes more industrialized and biosecurity becomes a top priority, the need for effective pharmaceutical solutions will remain critical. Industry leaders and emerging players alike are positioned to benefit from this trend by delivering innovative, accessible, and compliant products that support sustainable poultry health management across global markets.